NCT01270724

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Nationwide Children's Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.

Conditions

• CNS Germ Cell Tumor

Interventions

Type	Name	Description
DRUG	Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).	Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.

Timeline

• Start date: 2010-08-01
• Primary completion: 2019-10-23
• Completion: 2019-12-09
• First posted: 2011-01-05
• Last updated: 2025-10-27
• Results posted: 2025-10-27

Locations

5 sites across 1 country: United States